Drugs / pNGVL4a-SigE7(detox)HSP70
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00788164 | Nov 2008 → Aug 2023 | cervical cancer, dysplasia of cervix, human papilloma virus infection | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pNGVL4a-sig/E7(detox)/HSP70 | “Intramuscular vaccination of women with high-grade cervical intraepithelial neoplasia (CIN2/3) twice with a naked DNA vaccine, pNGVL4a-sig/E7(detox)/HSP70, and a single boost...” PMID 26420854 ↗ Sep 20152“HPV16 E7-targeted DNA vaccine pNGVL4a-SigE7(detox)HSP70 (DNA vaccine pBI-1)” PMID 33468698 ↗ Jan 2021 |
| Known as | pBI-1 | “HPV16 E7-targeted DNA vaccine pNGVL4a-SigE7(detox)HSP70 (DNA vaccine pBI-1)” PMID 33468698 ↗ Jan 2021 |
| Modality | Vaccine | “HPV16 E7-targeted DNA vaccine pNGVL4a-SigE7(detox)HSP70 (DNA vaccine pBI-1)” PMID 33468698 ↗ Jan 2021 |
| Route | Intramuscular | “Given intramuscularly” NCT00788164 ↗ |